We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01480648
First Posted: November 29, 2011
Last Update Posted: November 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Boehringer Ingelheim
  Purpose
This first-in-man trial forms the basis for potential clinical development of BI 144807 in the indications of asthma and allergic rhinitis. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising doses of BI 144807 will be assessed in healthy male volunteers.

Condition Intervention Phase
Healthy Drug: BI 144807 Placebo Drug: BI 144807 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 144807 Powder in Bottle (1 to 1200 mg) in Healthy Male Volunteers in a Randomised, Single-blind, Placebo-controlled Trial

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • All adverse events [ Time Frame: up to 14 days postdose ]
  • Number of participants with clinically significant changes in vital signs [ Time Frame: up to 14 days postdose ]
  • Number of participants with clinically significant changes in ECG [ Time Frame: up to 14 days postdose ]
  • Number of participants with clinically significant changes in laboratory tests [ Time Frame: up to 14 days postdose ]
  • Number of participants with clinically significant changes in physical examination [ Time Frame: up to 14 days postdose ]
  • Number of participants tolerating BI 144807 [ Time Frame: up to 14 days postdose ]

Secondary Outcome Measures:
  • Cmax (maximum measured concentration of the analyte in plasma) [ Time Frame: up to 72h postdose ]
  • tmax (time from dosing to maximum measured concentration) [ Time Frame: up to 72h postdose ]
  • AUC0-8 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) [ Time Frame: up to 72h postdose ]
  • AUC(0-tz) (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) [ Time Frame: up to 72h postdose ]
  • t1/2 (terminal half-life of the analyte in plasma) [ Time Frame: up to 72h postdose ]

Enrollment: 74
Study Start Date: November 2011
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI144807
Subjects receive a single oral dose of BI144807solution
Drug: BI 144807
single dose (low to high dose)
Placebo Comparator: Placebo
Subjects receive a single oral dose of placebo solution
Drug: BI 144807 Placebo
Placebo that represents BI drug

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

1. healthy male subjects

Exclusion criteria:

1. any relevant deviation from healthy conditions

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01480648


Locations
Germany
1313.1.1 Boehringer Ingelheim Investigational Site
Biberach, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01480648     History of Changes
Other Study ID Numbers: 1313.1
2011-002560-24 ( EudraCT Number: EudraCT )
First Submitted: November 21, 2011
First Posted: November 29, 2011
Last Update Posted: November 1, 2013
Last Verified: October 2013